Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | 0.00 | — | — | — |
P/S ratio |
3.07 | — | — | — | 5.75 | — | — | — |
Altman Z-Score |
(96.86) | — | — | — | (14.38) | — | — | — |
Altman Z″-Score (non-manufacturers) |
(243.73) | — | — | — | (34.30) | — | — | — |
P/FCF ratio |
0.00 | — | — | — | 0.00 | — | — | — |
P/Operating CF |
(3.54) | — | — | — | (5.33) | — | — | — |
P/B ratio |
0.00 | — | — | — | 0.00 | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | 0.00 | — | — | — |
EV/Sales |
2.30 | — | — | — | 3.66 | — | — | — |
EV/EBITDA |
0.00 | — | — | — | 0.00 | — | — | — |
EV/Operating CF |
(0.21) | — | — | — | (0.90) | — | — | — |
EV/FCF |
(0.21) | — | — | — | (0.90) | — | — | — |
Quick Ratio |
0.10 | 0.62 | 9.50 | 2.11 | 0.95 | 0.01 | 4.00 | 0.18 |
Current Ratio |
0.14 | 0.90 | 10.07 | 2.35 | 1.03 | 0.04 | 4.16 | 0.32 |
Net Debt/EBITDA |
0.09 | 0.10 | 1.12 | 0.45 | 0.34 | 0.01 | 0.60 | 0.15 |
Debt/Assets |
0.00% | 35.98% | 21.43% | 41.69% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.77) | 0.31 | 2.84 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.16 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.63 | 0.84 | 0.74 | 1.09 | 0.38 | 0.46 | (32.93) | 1.85 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | (0.14) |
Interest Coverage |
(539.99) | (5,065.43) | (38.59) | (114.38) | (1,025.76) | (24.31) | (128.61) | (13.91) |
| 171.72% | (314.84%) | (220.55%) | (1,489.36%) | 2,175.05% | 2,074.63% | (20.41%) | 85.14% | |
| (269.01%) | (138.42%) | (130.80%) | (133.62%) | (908.21%) | (100.77%) | 5.63% | (119.11%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
113.00% | 2,960.31% | (87.86%) | (189.78%) | (16,117.92%) | 73.84% | 6.31% | 99.16% |
Average Days of Receivables |
0.00 | — | — | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
1,367.09% | 0.00% | 0.00% | 0.00% | 6,016.80% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
571.27% | 0.00% | 0.00% | 0.00% | 2,015.73% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
181.03% | 0.00% | 0.00% | 0.00% | 122.40% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(4.96) | — | — | — | 0.00 | — | — | — |
Graham Number |
4,399.43 | — | — | — | 714.56 | — | — | — |
Earnings Yield |
(556.60%) | — | — | — | (333.92%) | — | — | — |
Free Cash Flow Yield |
(353.67%) | — | — | — | (70.84%) | — | — | — |
Revenue per Share |
57.52 | 0.00 | 0.00 | 0.00 | 70.75 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(624.33) | (2,223.97) | (2,076.06) | (1,802.84) | (3,642.45) | (1,976.25) | (105,710.00) | (2.11) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(624.33) | (2,223.97) | (2,076.06) | (1,802.84) | (3,642.45) | (1,976.25) | (105,710.00) | (2.12) |
Cash per Share |
98.15 | 560.76 | 3,336.19 | 1,350.17 | 1,936.04 | 52.50 | 63,310.00 | 0.32 |
Shareholders Equity per Share |
(874.93) | (383.07) | 2,428.94 | 221.72 | (1.32) | (5,882.50) | 43,710.00 | (1.15) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(874.93) | (383.07) | 2,428.94 | 221.72 | (1.32) | (5,882.50) | 43,710.00 | (1.15) |
Free Cash Flow |
(23.91) | (61.60) | (48.99) | (20.91) | (19.30) | (1.58) | (10.57) | (13.79) |
Working Capital |
(33.52) | (2.48) | 75.17 | 10.07 | 0.32 | (4.71) | 5.01 | (7.66) |
Capital Expenditures |
— | — | — | — | — | — | — | (0.01) |
Net Current Asset Value |
(33.52) | (10.68) | 57.28 | 2.57 | (0.01) | (4.71) | 4.26 | (8.58) |
EV/EBIT |
0.00 | — | — | — | 0.00 | — | — | — |
Capex to Sales |
0.00 | — | — | — | 0.00 | — | — | 0.00 |
Price to Operating Income |
0.00 | — | — | — | 0.00 | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 11.68 | 0.00 | 0.00 | — | 0.00 | 1.48 | 0.65 |
Cash ROIC |
80.37% | (470.04%) | (31.83%) | (81.93%) | (188.27%) | 33.90% | (98.78%) | 254.10% |
Accounts Receivable Turnover |
0.00 | — | — | — | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | — | — | — | 0.00 | 0.00 |
Average Payables |
10.01 | 2.66 | 1.79 | 1.34 | 1.51 | 1.14 | 0.41 | 1.17 |
Average Assets |
14.08 | 53.12 | 50.50 | 14.30 | 5.64 | 3.45 | 5.70 | 6.24 |
Average Common Equity |
(22.06) | 23.36 | 29.95 | 1.28 | (2.36) | (0.17) | (1.57) | (8.73) |
Columns are period end dates